Picard to Attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum November 20, 2025, in New York City

TUCSON, Ariz., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will attend the Canaccord Genuity (CG) MedTech, Diagnostics and Digital Health & Services Forum to be held on November 20, 2025, in New York, NY.

Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical, Inc., will be available for one-on-one meetings with investors; to schedule a meeting, please contact your CG sale representative to set up a meeting with management.

About Picard Medical and SynCardia

Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.

For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.

Contact:

Investors Eric Ribner
Managing Director
LifeSci Advisors LLC
[email protected]

Picard Medical, Inc./SynCardia Systems, LLC [email protected]

General/Media Brittany Lanza
[email protected]